Last reviewed · How we verify

Dipexium Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Dipexium Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Topical pexiganan cream 0.8% Topical pexiganan cream 0.8% phase 3 Antimicrobial peptide Bacterial cell membrane Infectious Disease / Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abeona Therapeutics, Inc · 1 shared drug class
  2. Guangzhou Yipinhong Pharmaceutical CO.,LTD · 1 shared drug class
  3. Maruho Co., Ltd. · 1 shared drug class
  4. Tufts Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dipexium Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Dipexium Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dipexium-pharmaceuticals-inc. Accessed 2026-05-16.

Related